Revenue segments as reported by the company.

Revenues including Excise Taxes

Excise Taxes on products

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Amortization of intangibles

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Philip Morris

Malboro is an American brand of cigarettes, currently owned and manufactured by Philip Morris USA. It is sold globally and one of the most popular ciggarettes in the world.

Malboro

Philip Morris International, Inc. is a holding company, which engages in the business of delivering a smoke-free future and evolving a portfolio for the long term to include products outside of the tobacco and nicotine sector. It operates through the following geographical segments: Europe Region (Europe), South and Southeast Asia, Commonwealth of Independent States, Middle East, and Africa Region (SSEA, CIS, and MEA), East Asia, Australia, and PMI Duty Free Region (EA, AU, and PMI DF), and Americas Region (Americas). The Europe segment includes all the European Union countries, Switzerland, the United Kingdom, Ukraine, Moldova, and Southeast Europe. The SSEA, CIS, and MEA segment focuses on South and Southeast Asia, the African continent, the Middle East, Turkey, Israel, Central Asia, Caucasus, and Russia. The EA, AU, and PMI DF segment is involved in the consolidation of international duty-free business with East Asia and Australia. The Americas segment is comprised of the United States, Canada, and Latin America. The company was founded by Philip Morris in 1847 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Philip Morris excels in 2022, eyes growth through sustainability

Philip Morris navigated challenges in 2022 to deliver strong results and is poised for continued growth in 2023. By focusing on smoke-free products, sustainability, and strategic investments, PM is positioning itself for long-term success despite geopolitical and economic headwinds.

Philip Morris beats Q1 expectations with strong IQOS performance

Philip Morris delivered a strong Q1 performance driven by IQOS, ZYN, and combustibles.
Despite challenges like currency devaluation and volume declines, PMI remains optimistic.
Future opportunities lie in organic growth, commercial investments, and smoke-free product expansion.
Overall, PMI aims for continued growth in 2023 with a focus on key product lines.

Philip Morris (PM) reports record earnings, eyes growth in smoke-free products

Philip Morris International (PM) delivered strong financial performance in Q2 2023, driven by the success of ZYN and IQOS. The company is focused on maximizing the potential of its smoke-free business, particularly IQOS and ZYN, while addressing challenges in deleveraging the balance sheet and potential M&A. Opportunities for growth include expanding market presence for ILUMA and maintaining strong performance in combustibles.

Philip Morris reports strong Q3 earnings driven by smoke-free products

Philip Morris International's Q3 performance was robust, driven by smoke-free products like IQOS and ZYN. Despite challenges like inventory concerns and currency impacts, the company is focused on growth opportunities and investment in key markets. Strong outlook for organic income growth and continued focus on reduced-risk products.

Philip Morris excels in smoke-free products, eyes global expansion

Philip Morris delivered strong results in 2023, driven by smoke-free products. Despite challenges like currency impacts and regulatory concerns, the company aims for continued growth and market expansion.

Philip Morris (PM) surpasses Q1 expectations, faces currency challenges

Philip Morris (PM) delivered strong Q1 2024 results driven by IQOS and ZYN businesses, exceeding expectations across key financial metrics. The company faces challenges from currency headwinds, geopolitical factors, and supply chain tensions. Strategic pricing actions and market expansion present growth opportunities.

Philip Morris excels in Q2 2024 with strong product growth

Philip Morris' Q2 2024 performance showcased strong growth in key products and markets, with a focus on responsible marketing and growth strategies for smoke-free offerings. The company remains optimistic about future growth prospects despite challenges.

Philip Morris excels in Q3, raises guidance on strong performance

Philip Morris International Inc. reported exceptional Q3 results, surpassing expectations and demonstrating strong performance across its portfolio. Despite challenges such as supply constraints and illicit product concerns, the company remains focused on growth opportunities, including expanding production capacity and advancing sustainability efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Philip Morris International Inc. (NYSE:PM) has bought 22.61% of Vectura Group PLC (AIM:VEC) as shareholders have been urged to vote against the 165p per share takeover offer. In a somewhat aggressive move, the tobacco giant acquired 135mln shares at 165p each and called for institutional investors interested in selling more.

Philip Morris buys big chunk of Vectura amid takeover outcry

Tobacco group Philip Morris International on Wednesday said it had bought 22.61% of U.K.-based respiratory drug developer Vectura in a market purchase.

Marlboro maker Philip Morris buys stake in British asthma inhaler firm

Vectura Group PLC shareholders have been urged to vote against the 165p per share offer put forward by cigarette maker Philip Morris International. A group of health experts led by Asthma UK and the British Lung Foundation said that the takeover would “significantly hamper Vectura's ability to continue operating as a viable, research-oriented business”.

Vectura shareholders urged to vote against Philip Morris International deal

Starbucks

NVIDIA

Exxon Mobil

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Starbucks among others.

Starbucks Ranked Among Today's Trending Stocks

Philip Morris International Inc (NYSE: PM) has launched IQOS ILUMA to their portfolio of smoke-free products for adults who would otherwise continue to smoke or use nicotine products. The IQOS ILUMA series offers two devices in Japan: IQOS ILUMA PRIME and IQOS ILUMA, available for pre-order on IQOS.com beginning August 17, 2021, and for purchase at stores on August 18, 2021.

Philip Morris Launches Smoke Free Product IQOS ILUMA In Japan

LAUSANNE, Switzerland--(BUSINESS WIRE)--Philip Morris International Launches New IQOS ILUMA in Japan to Accelerate the Achievement of a Smoke-Free Future

Philip Morris International Launches New IQOS ILUMA in Japan to Accelerate the Achievement of a Smoke-Free Future

Amazon

British American Tobacco

Enbridge

Enterprise Products Partners

Magellan Midstream Partners

Altria

Value stocks have underperformed for 13 years and given up all their relative gains vs. growth since 1974. Both value bulls and bears have good reasons to argue value is about to have an epic decade or that the value factor is dead forever.

7 High-Yield Blue-Chips That Can Help You Retire Rich

LAUSANNE, Switzerland--(BUSINESS WIRE)--Philip Morris International Enters Tender Period with Vectura Shareholders Following Unanimous Recommendation by Vectura Board

Philip Morris International Enters Tender Period with Vectura Shareholders Following Unanimous Recommendation by Vectura Board

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Illinois Tool Works

Leggett & Platt

Norfolk Southern

Realty Income Corp

Occidental Petroleum

J. M. Smucker

Schlumberger

Scotts Miracle-Gro

T. Rowe Price Group

TotalEnergies SE

ViacomCBS

In July, we received $771.96 in dividend income! Our top dividend payment for the month was a HUGE special dividend payment from T. Rowe Price.

Dividend Income Summary: Bert's July 2021 Summary

The Marlboro Man must be wondering if he's going to be replaced by a scientist in a lab coat. That's because Philip Morris International Inc. ( PM , Financial) seems intent on at least partially transforming itself into a health care company.

Philip Morris Further Expands Its Reach Into Health Care

Vectura Group said on Thursday it plans to back tobacco giant Philip Morris International's 1.1 billion pounds ($1.52 billion) offer for the British drugmaker, days after private equity firm Carlyle decided against raising its bid.

UK's Vectura to back $1.52 billion takeover offer from Philip Morris

AGNC Investment

Johnson & Johnson

Walgreens

One of the best ways to fight back against inflation is to put your cash to work in time-tested companies.

4 Value Stocks That'll Help You Trounce Inflation

Philip Morris (PM) acquires OtiTopic to expand offerings in the inhaled therapeutics and respiratory drug delivery platform. The move is part of the company's Beyond Nicotine strategy.

Philip Morris (PM) Boosts Beyond Nicotine Options With OtiTopic

Carlyle Group

Vectura Group PLC is facing a rare takeover auction whereby Philip Morris International Inc. and Carlyle Group have five working days to submit new offers.

Vectura to start rare takeover auction to end Philip Morris, Carlyle Group bidding war

Philip Morris International Inc. (PMI) (NYSE: PM) has acquired OtiTopic, a Los Angeles-headquartered respiratory drug development company. The financial terms of the transaction were not disclosed.

Philip Morris International Acquires Inhaled Drug Developer OtiTop

Philip Morris International Inc (NYSE: PM) has acquired OtiTopic , a U.S. respiratory drug development company, for an undisclosed sum. OtiTopic has late-stage inhalable acetylsalicylic acid (ASA) treatment ASPRIHALE for acute myocardial infarction.

Philip Morris Acquires Respiratory Drug Development Firm OtiTopic For Undisclosed Sum

(Reuters) -The takeover battle for drugmaker Vectura will enter a rare head-to-head auction process if private equity group Carlyle and tobacco giant Philip Morris do not make final bids by Tuesday, according to a British regulator.

Philip Morris, Carlyle could fight it out for UK's Vectura in auction ring

LAUSANNE, Switzerland--(BUSINESS WIRE)--Philip Morris International Inc. (PMI) (NYSE: PM) today announced its acquisition of OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction. If approved, the treatment can address the significant unmet medical need of the over 83 million people, in the U.S. alone, at intermediate to high risk for myocardial infarction. “The acquisition of OtiTopic is an excitin

Philip Morris International Acquires Inhaled Drug Specialist OtiTopic; Growing Pipeline of “Beyond Nicotine” Inhaled Therapeutic Products

Philip Morris International Inc. said Monday that it has increased its offer for Vectura Group PLC to 1.02 billion pounds ($1.42 billion), trumping Friday's offer from Carlyle Europe Partners V for the U.K. pharmaceutical company.

Philip Morris lifts Vectura offer to $1.4 billion, trumping Carlyle Europe bid

Vectura Group PLC has received a higher bid from Philip Morris International Inc. after trumping its previous offer for Carlyle Group.

Vectura bidding war continues as Philip Morris comes back with higher offer

Philip Morris International Inc (NYSE: PM) is raising the stakes in the race for Vectura Group PLC (OTC: VEGPF) with a bid valuing the company at more than $1.41 billion, Reuters reports.   In May, U.S.-based Carlyle Group Inc (NASDAQ: CG) had agreed to buy Vectura.

Philip Morris Raises Bid For UK Inhaler Group Vectura

CareTrust REIT

Chevron

Imperial Brands PLC

Omega Healthcare Investors

Sabra Health Care

Ventas

Welltower

There are always bargains to be had in bull and bear markets alike. In this article, I highlight 3 compelling buys with high dividends that are well covered.

3 Strong Buys For A Rich Retirement, Up To 9% Yield

Philip Morris has raised its bid for British drugmaker Vectura to 165 pence ($2.29) per share, the tobacco company said on Sunday.

Philip Morris lifts bid for UK's Vectura to 165 pence per share

Both companies are attractive for dividend investors offering a stable yield of 5-8%. BTI is trading at a pretty inexpensive valuation compared to PM.

Philip Morris Vs. British American Tobacco

Shares in Vectura Group PLC spike 6% to 163.2p as the inhaled drug specialist got an improved takeover offer.  Directors of Vectura have agreed an increased recommended cash offer from private equity group Carlyle of 155p per share in cash, valuing the group at roughly £958mln.

News for Philip Morris Stock (PM)